Emergent Biosolutions (EBS) Misses Q4 EPS by 1c; Issues Mixed Outlook
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.34 -0.6%
EPS Growth %: -31.3%
Financial Fact:
Total revenues: 142.91M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: -31.3%
Financial Fact:
Total revenues: 142.91M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q4 EPS of $0.44, $0.01 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $94.6 million versus the consensus estimate of $95.09 million.
Emergent Biosolutions sees FY2013 revenue of $40-50 million, versus the consensus of $60 million.
Emergent Biosolutions sees FY2013 revenue of $290-310 million, versus the consensus of $300.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Emergent Biosolutions sees FY2013 revenue of $40-50 million, versus the consensus of $60 million.
Emergent Biosolutions sees FY2013 revenue of $290-310 million, versus the consensus of $300.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- Driven Brands (DRVN) Tops Q4 EPS by 2c, Misses on Revenue; Offers FY26 Guidance
- Carvana (CVNA) PT Lowered to $85 at RBC Capital
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
